Blog

The Canadian Drug Expert Committee (CDEC) is an advisory body to CADTH. CDEC makes drug-related recommendations and provides drug-related advice ...

[:content [\4 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \  \- \  \N \I \C \E \space \h \a \s \space \a \n \n \o \u \n \c \e \d \space \i \t \space \i \n \t \e \n \d \s \space \t \o \space \r \e \c \o \m \m \e \n \d \space \a \l \e \m \t \u \z \u \m \a \b \space \f \o \r \space \a \d \u \l \t \s \space \w \i \t \h \space \a \c \t \i \v \e \space \r \e \l \a \p \s \i \n \g \space \r \e \m \i \t \t \i \n \g \space \m \u \l \t \i \p \l \e \space \s \c \l \e \r \o \s \i \s \. " ..."]]

PHARMAC is seeking feedback on a provisional agreement with Celgene Pty Ltd. In summary, this proposal is, from 1 September ...

CADTH has received notice of a pending submission from Celgene for Otelza (apremilast) for patients with psoriatic arthritis.  For information about ...

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in ...

Scottish patients with a severe form of relapsing remitting multiple sclerosis will become the first in the UK to get ...

19 June 2014 - Below is a list of forthcoming submissions that have recently been added to the SMC's work programme. ...

In order to avoid providing a focus for political debate or detracting attention from the general election campaign, NICE will ...

PHARMAC will begin funding for the prostate cancer treatment abiraterone acetate (Zytiga) from 1 May 2015, potentially benefiting up to 1,000 ...

In early 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ipilimumab ...

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the Scottish Medicines ...

Cost regulators for the National Health Service in England and Wales have endorsed funding for Roche’s cancer therapy Gazyvaro, Bayer’s ...

In final guidance published today NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare), in combination with clopidogrel and aspirin, or with ...

The Pan Canadian Expert Review Committee has recommended the funding of pomalidomide (Pomalyst) for patients with relapsed and/or refractory multiple ...